S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of S1 combination with
Anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence
after at least one standard chemotherapy.